Voltaren Gel (diclofenac sodium topical gel) 1% – Hepatic Effects Labeling Changes
Audience: Rheumatological healthcare professionals, pharmacists
Endo, Novartis and FDA notified healthcare professionals of revisions to the Hepatic Effects section of the prescribing information to add new warnings and precautions about the…
Related posts:
- Orlistat (marketed as Alli and Xenical): Labeling Change Audience: Family Practice healthcare professionals, patients/consumers FDA notified healthcare professionals...
- Proton Pump Inhibitors (PPI): Class Labeling Change Audience: Family Practice, consumers including Nexium, Dexilant, Prilosec, Zegerid, Prevacid,...
- Voltaren Gel Linked to Severe Liver Damage Some patients using Voltaren Gel have developed drug-induced hepatoxicity soon...
- Valproate Sodium and related products (valproic acid and divalproex sodium): Risk of Birth Defects Audience: Neurological and Obstetrical healthcare professionals The FDA notified health...
- Dexferrum (iron dextran injection) – Labeling Change Audience: Hematological healthcare professionals, hospital risk managers American Regent and FDA...
Permalink Tags: Dangerous Drugs
